Meeting
2022 ASCO Annual Meeting
Phase 1 study of C019199, an oral CSF-1R/DDRs/VEGFR2 multiple kinase inhibitor, to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with advanced solid tumors, including tenosynovial giant cell tumor.
Authors
Lin Shen
Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing, China
Lin Shen , Feng Ye , Jifang Gong
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Small Molecules
Clinical Trial Registration Number
CTR20202045
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS3177)
DOI
10.1200/JCO.2022.40.16_suppl.TPS3177
Abstract #
TPS3177
Poster Bd #
155b
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
A phase 1 first-in-human study of XL092 administered alone or in combination with immune checkpoint inhibitors (ICIs) in patients (pts) with inoperable locally advanced or metastatic solid tumors: Description of genitourinary (GU) expansion cohorts.
First Author: Manish Sharma
Poster
2021 ASCO Annual Meeting
A phase 1, multicenter, open-label, dose-escalation, safety, pharmacodynamic, pharmacokinetic study of Q702 with a cohort expansion at the RP2D in patients with advanced solid tumors.
First Author: Angela Tatiana Alistar
Poster
2020 ASCO Virtual Scientific Program
A phase I, first-in-human, open-label, dose‑escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP‑1287 administered daily to patients with advanced solid tumors.
First Author: Ben George
Poster
2017 ASCO Annual Meeting
Phase I study to evaluate the tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) of PM01183 (Lurbinectedin) in combination with olaparib in patients with advanced solid tumors.
First Author: Andres Poveda